Target intelligence / Profile preview

MICAL2 antisense RNA 1 (MICAL2-AS1)

Target
MICAL2-AS1
Molecular classification
Non-coding RNA, Long non-coding RNA (lncRNA), Antisense RNA
01

Overview

MICAL2 antisense RNA 1 (MICAL2-AS1) is a long non-coding antisense RNA transcribed from the genomic region opposite to the MICAL2 gene. As an antisense RNA, it is involved in the regulation of gene expression, primarily modulating the transcript and function of its corresponding sense gene, MICAL2, which encodes an enzyme involved in actin cytoskeletal regulation and is implicated in various cancers[3]. Antisense RNAs like MICAL2-AS1 can influence gene expression at levels including transcription, mRNA stability, and translation, often acting in cis (on the same chromosome) or trans (on different chromosomes)[3]. Their primary mechanism includes forming RNA:RNA duplexes, influencing chromatin structure, epigenetic modifications, or interfering with transcriptional machinery. While the detailed functions and disease relevance of MICAL2-AS1 are still emerging, it may play regulatory roles in cancer by controlling MICAL2 expression, and it could serve as a potential biomarker in research contexts. There are currently no drugs targeting MICAL2-AS1 directly, and it is not considered a classical drug target such as a receptor or enzyme.

Other names
MICAL2-AS1MICAL2 antisense RNA 1
02

Mechanism of action

Not applicable (no known direct drugs targeting this antisense RNA; acts through RNA-RNA or RNA-DNA interactions, modulates expression of MICAL2 and possibly neighboring genes)

03

Biological functions

Regulation of gene expressionEpigenetic regulationModulation of chromatin structureRegulation of transcription
04

Disease associations

Cancer (various types)Potential roles in imprinting disordersOther (context-dependent as a regulator of sense genes)
05

Safety considerations

Not established for direct targetinggeneral lncRNA/antisense targeting can have off-target or unintended epigenetic effects
06

Biomarkers

Potential lncRNA biomarker in cancer (needs more evidence)none established for clinical monitoring

Beyond the preview

Go deeper on MICAL2 antisense RNA 1 (MICAL2-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MICAL2 antisense RNA 1 (MICAL2-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call